US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Aclarion, Inc. - Warrant
(NQ:
ACONW
)
0.0256
UNCHANGED
Delayed Quote
Updated: 3:25 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aclarion, Inc. - Warrant
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
November 14, 2024
Via
ACCESSWIRE
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
February 16, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
October 25, 2022
Via
ACCESSWIRE
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
October 24, 2022
Via
ACCESSWIRE
Aclarion Announces Participation at the NASS 37th Annual Meeting
October 10, 2022
Via
ACCESSWIRE
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
October 03, 2022
Via
ACCESSWIRE
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
September 19, 2022
Via
ACCESSWIRE
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
July 20, 2022
Via
ACCESSWIRE
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
July 20, 2022
Initial findings from the EVAL study are expected to be released in Q4 2022
From
Aclarion Inc.
Via
AccessWire
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
June 22, 2022
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years
From
Aclarion Inc.
Via
AccessWire
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
April 26, 2022
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy...
From
Aclarion Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
